Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 2
1975 3
1980 1
1987 1
1988 1
1990 1
1991 2
1993 2
1994 1
1995 1
1996 1
1997 2
1999 6
2000 9
2001 3
2002 5
2003 7
2004 6
2005 7
2006 8
2007 10
2008 11
2009 10
2010 21
2011 15
2012 10
2013 21
2014 18
2015 22
2016 23
2017 16
2018 18
2019 17
2020 24
2021 27
2022 22
2023 22
2024 23

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

351 results

Results by year

Filters applied: . Clear all
Page 1
[Aconite poisoning].
Fujita Y, Terui K, Takahashi T, Endo S. Fujita Y, et al. Among authors: terui k. Chudoku Kenkyu. 2013 Jun;26(2):102-6. Chudoku Kenkyu. 2013. PMID: 23855240 Review. Japanese. No abstract available.
Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms.
Sato T, Yoshida K, Toki T, Kanezaki R, Terui K, Saiki R, Ojima M, Ochi Y, Mizuno S, Yoshihara M, Uechi T, Kenmochi N, Tanaka S, Matsubayashi J, Kisai K, Kudo K, Yuzawa K, Takahashi Y, Tanaka T, Yamamoto Y, Kobayashi A, Kamio T, Sasaki S, Shiraishi Y, Chiba K, Tanaka H, Muramatsu H, Hama A, Hasegawa D, Sato A, Koh K, Karakawa S, Kobayashi M, Hara J, Taneyama Y, Imai C, Hasegawa D, Fujita N, Yoshitomi M, Iwamoto S, Yamato G, Saida S, Kiyokawa N, Deguchi T, Ito M, Matsuo H, Adachi S, Hayashi Y, Taga T, Saito AM, Horibe K, Watanabe K, Tomizawa D, Miyano S, Takahashi S, Ogawa S, Ito E. Sato T, et al. Among authors: terui k. Blood. 2024 Jun 20;143(25):2627-2643. doi: 10.1182/blood.2023022247. Blood. 2024. PMID: 38513239
Tsunami lung.
Inoue Y, Fujino Y, Onodera M, Kikuchi S, Shozushima T, Ogino N, Mori K, Oikawa H, Koeda Y, Ueda H, Takahashi T, Terui K, Nakadate T, Aoki H, Endo S. Inoue Y, et al. Among authors: terui k. J Anesth. 2012 Apr;26(2):246-9. doi: 10.1007/s00540-011-1273-6. Epub 2011 Nov 6. J Anesth. 2012. PMID: 22057370
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia.
Iyoda S, Yoshida K, Shoji K, Ito N, Tanaka M, Nannya Y, Yamato G, Tsujimoto S, Shiba N, Hayashi Y, Shiozawa Y, Shiraishi Y, Chiba K, Okada A, Tanaka H, Miyano S, Koga Y, Goto H, Moritake H, Terui K, Ito E, Kiyokawa N, Tomizawa D, Taga T, Tawa A, Takita J, Nishikori M, Adachi S, Ogawa S, Matsuo H. Iyoda S, et al. Among authors: terui k. Leukemia. 2024 Jul;38(7):1609-1612. doi: 10.1038/s41375-024-02244-4. Epub 2024 Apr 18. Leukemia. 2024. PMID: 38632314 No abstract available.
Molecular pathogenesis in Diamond-Blackfan anemia.
Ito E, Konno Y, Toki T, Terui K. Ito E, et al. Among authors: terui k. Int J Hematol. 2010 Oct;92(3):413-8. doi: 10.1007/s12185-010-0693-7. Epub 2010 Sep 30. Int J Hematol. 2010. PMID: 20882441 Review.
High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia.
Tomizawa D, Matsubayashi J, Iwamoto S, Hiramatsu H, Hasegawa D, Moritake H, Hasegawa D, Terui K, Hama A, Tsujimoto SI, Kiyokawa N, Miyachi H, Deguchi T, Hashii Y, Iijima-Yamashita Y, Taki T, Noguchi Y, Koike K, Koh K, Yuza Y, Moriya Saito A, Horibe K, Taga T, Tanaka S, Adachi S. Tomizawa D, et al. Among authors: terui k. Leukemia. 2024 Jan;38(1):202-206. doi: 10.1038/s41375-023-02075-9. Epub 2023 Nov 6. Leukemia. 2024. PMID: 37926712 No abstract available.
The role of STAT3 in liver regeneration.
Terui K, Ozaki M. Terui K, et al. Drugs Today (Barc). 2005 Jul;41(7):461-9. doi: 10.1358/dot.2005.41.7.893622. Drugs Today (Barc). 2005. PMID: 16193099 Review.
A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20).
Tomizawa D, Tsujimoto SI, Tanaka S, Matsubayashi J, Aoki T, Iwamoto S, Hasegawa D, Nagai K, Nakashima K, Kawaguchi K, Deguchi T, Kiyokawa N, Ohki K, Hiramatsu H, Shiba N, Terui K, Saito AM, Kato M, Taga T, Koshinaga T, Adachi S. Tomizawa D, et al. Among authors: terui k. Jpn J Clin Oncol. 2022 Oct 6;52(10):1225-1231. doi: 10.1093/jjco/hyac105. Jpn J Clin Oncol. 2022. PMID: 35809896 Clinical Trial.
351 results